Experiment: does MLL-AF4 transform a staged fetal progenitor when it cannot transform cord blood?
also called developmental window transformation assay · fetal versus postnatal target cell
Put the same fusion gene into blood stem cells taken from different stages of development and see which ones turn into leukaemia. If only the earliest ones do, the missing ingredient is the age of the cell, not a second broken gene.
The same thing, for a scientist
A staged-target-cell transformation experiment with a mutational-substitution arm. Express MLL-AF4 at near-endogenous level from a single-copy, doxycycline-independent cassette in four human progenitor sources: first/second-trimester fetal liver CD34+, fetal bone marrow CD34+, cord-blood CD34+ (the published negative control [E1]), and adult mobilised peripheral blood CD34+. Transplant into NSG-SGM3 or MISTRG recipients and follow to 30 weeks, well beyond the 16 weeks at which the published cord-blood experiment ended. Readouts are leukaemic transformation, serial replating, and secondary transplantation. A parallel substitution arm adds one epigenetic-regulator lesion recurrent in non-infant KMT2A-rearranged disease to the cord-blood arm, testing whether adult mutations can stand in for fetal context. Where fetal tissue is not obtainable, an iPSC-derived fetal-like definitive haematopoietic progenitor substitutes, with the fidelity of that model becoming the principal caveat.
Why the design differs from what has been done1 deeper
Three deliberate departures from the published cord-blood work 1: (1) staged fetal cells, which is the actual variable of interest and which no published human MLL-AF4 experiment has used; (2) near-endogenous expression from a single integration, because lentiviral overexpression can be both too high (toxic, or driving a non-physiological program) and wrongly timed; (3) 30-week follow-up with secondary transplant, because a 16-week negative in a disease whose human latency is measured in months post-birth is not a long enough window in a xenograft.
Controls and interpretation traps
Fetal progenitors engraft better than adult ones regardless of any oncogene, so the primary endpoint must be transformation (serial replating plus secondary transplant plus an expanded immature population), never engraftment level. Empty-vector fetal arms are mandatory. A positive result in fetal cells with an unusually high vector copy number is not a positive result; copy number must be matched across arms and reported.
| design | Single-copy near-endogenous MLL-AF4 expression in four staged human CD34+ sources (fetal liver, fetal marrow, cord blood, adult mobilised) plus a cord-blood arm carrying one recurrent epigenetic-regulator lesion; xenotransplantation into NSG-SGM3 or MISTRG with 30-week follow-up and secondary transplant |
|---|---|
| readout | leukaemic transformation, serial replating, secondary transplantation, immunophenotype, HOXA9/MEIS1 program score, H3K4me3/H3K27me3 bivalency at HOXA before transduction |
| controls | empty vector in every cell source; matched vector copy number across arms; engraftment explicitly excluded as an endpoint |
| cost tier | high |
| timeline | 18-24 months; fetal tissue access is the rate-limiting and jurisdiction-dependent step |
- A negative result in fetal cells would be genuinely informative but would also leave the field with no human model at all, which is where it has been for twenty years.
- Is first-trimester human fetal liver CD34+ tissue obtainable under this lab's regulatory environment? If not, the whole experiment rests on iPSC-derived surrogates and the interpretation weakens considerably.
- What is the right expression level? 'Near-endogenous' is easy to say and hard to achieve for a fusion with no normal counterpart; a knock-in at the endogenous KMT2A locus would be the rigorous version and adds a year.
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
MLL-AF4 in human cord-blood CD34+ cells enhances engraftment and clonogenicity but does not transform, over a 16-week xenograft follow-up, and FLT3 activation does not rescue this.
Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells · Montes R, Ayllon V, Prieto C, Bursen A, Prelle C, Romero-Moya D, et al. · Leukemia 2014What this evidence cannot show
This is the negative control arm of the proposed experiment, already run by others; the design above changes cell source, expression level and follow-up duration relative to it.
Evidence that argues against this (2)
- The premise that human cord blood is refractory to MLL-fusion transformation is partner-specific, not cell-source-specific, and this is the single biggest threat to the experiment's logic. Barabe et al. transduced primitive PRIMARY HUMAN haematopoietic cells with an MLL fusion gene and, on transplantation into immunodeficient mice, obtained myeloid or lymphoid acute leukaemias recapitulating features of the human diseases, sustained on serial transplantation by leukaemia-initiating cells that evolved from a germline-IgH to a rearranged-IgH configuration and retained bilineage potential. So the same human neonatal source that resists MLL-AF4 [E1] does transform with a different MLL fusion. Before spending 18-24 months on fetal tissue access, the design should include an MLL-ENL positive-control arm in cord blood; if that arm transforms and the MLL-AF4 arm does not in the same experiment, the variable under test is the partner, and the fetal-window hypothesis is not the explanation the negative result demands. Read: abstract only. Barabe F et al. 2007
- The published negative is broader than the FLT3 arm and should be cited as such. Prieto et al. tested whether activated KRAS(G12V) cooperates with MLL-AF4 in cord-blood CD34+ HSPCs: it did not immortalise them in clonogenic or differentiation assays, and after intrabone-marrow transplantation into immunodeficient mice, MLL-AF4 and KRAS(G12V) alone or together enhanced repopulation without impairing myeloid-lymphoid differentiation and did not initiate leukaemia. What KRAS did produce was extramedullary haematopoiesis with leukocytosis and CNS infiltration, both hallmarks of infant t(4;11) disease, supported by a cell-migration signature in patient transcriptomes; the authors concluded RAS mutation in MLL-AF4 B-ALL matters for maintenance rather than initiation. RAS is the ONLY recurrently mutated pathway in infant KMT2A-r ALL, so the most obvious cooperating lesion available from human genetics has now been tested and failed. The substitution arm in this design should therefore use epigenetic-regulator lesions and not RAS. Read: abstract only. Prieto C et al. 2016
- E2strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Non-infant KMT2A-rearranged leukaemia carries frequent epigenetic-regulator mutations that are nearly absent in infants, supplying the specific lesions for the substitution arm.
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias · Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. · Nature Genetics 2015What this evidence cannot show
20 older children; the specific recurrent lesions should be re-extracted from the paper's supplementary tables before the arm is designed, rather than taken from the abstract.
Evidence that argues against this (1)
- The infant-versus-older-child contrast is not a clean age split once sequencing depth and subgroup are accounted for. Targeted deep sequencing of 84 KMT2A-rearranged infants resolved five integrative clusters and found RAS-pathway mutations at 100% frequency, with the heaviest burden, in the most refractory cluster, and the NUMBER of RAS-pathway mutations predicting prognosis. Designing a substitution arm around 'lesions present in older children and nearly absent in infants' therefore risks substituting a lesion that is in fact present in a specific infant cluster, and the arm needs to be specified against cluster membership rather than against age. Isobe T et al. 2022
resolves a direct discrepancy surfaced by the counter-evidence pass: retroviral MLL-Af4 in human CD34+ cells gives a pro-B ALL model, but MLL-AF4 (and MLL-AF4 plus activated KRAS) in cord-blood CD34+ HSPCs enhances engraftment without initiating leukaemia
- related to →KMT2A::AFF1 (MLL-AF4), t(4;11)(q21;q23)
Counter-evidence (Barabe 2007, PMID 17463288): primary human haematopoietic cells expressing an MLL fusion DID generate serially transplantable myeloid or lymphoid acute leukaemia in mice, so the cord-blood refractoriness to MLL-AF4 is partner-specific, not source-specific -- the design needs an MLL-ENL positive-control arm before the fetal-window interpretation is admissible
Counter-evidence (Montes 2013, PMID 24240202; Prieto 2016, PMID 26837759): MLL-AF4 in human cord-blood CD34+ HSPCs does not transform, and neither FLT3 activation nor KRAS(G12V) rescues it -- a short clinical latency is compatible with a fast second event, not with no second event
staged-target-cell transformation assay with a mutational-substitution arm
fetal liver CD34+ is the primary experimental arm
substitution arm asks whether older children's epigenetic-regulator lesions replace fetal context
fetal programme maintained in infant but not childhood MLL-AF4 ALL
Counter-evidence (Isobe 2022, PMID 36042201): targeted deep sequencing of 84 KMT2A-rearranged infants found RAS-pathway mutations at 100% frequency and heaviest burden in the most refractory cluster, with mutation number prognostic -- the quiet-genome average hides a cluster in which a mutational second hit is universal